Disease Areas

For over a decade, Biogen has been committed to advancing ALS research to provide a deeper understanding of all forms of this devastating disease, which currently impacts an estimated 168,000 people worldwide. 

Our world-class neurology research and development organisation is pushing toward novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease. 

Friedreich ataxia (FA) is a genetic, debilitating and life-shortening neuromuscular disease. People living with FA experience progressive loss of coordination, muscle weakness, and fatigue, which progresses to muscle incapacitation and wheelchair reliance.

Biogen has pioneered the development of MS treatments for more than 25 years. We continue to innovate to advance treatments and improve outcomes for people with MS. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS. Our ongoing research into neurodegeneration and nerve repair will possibly help produce new therapeutic options for people living with MS.

Biogen is dedicated to enhancing the lives of those with SMA and their families through ongoing research, removing barriers to access and providing support programs. In December 2017, Biogen launched a collaboration with Ionis to identify new therapeutic options — specifically, new antisense oligonucleotide (ASO) candidates, which are designed to treat SMA — for those impacted by this condition.